Valproate leads to higher response rate at 3 weeks (primary efficacy outcome) compared with placebo (high certainty).
Valproate showed no clear difference in dropout rate ‐ All‐cause At 4‐6 weeks (secondary acceptability… compared with placebo (low certainty).
Valproate showed no clear difference in response rate at 3 weeks (primary efficacy outcome) compared with lithium (moderate certainty).
Valproate showed no clear difference in number of participants with any adverse event at 2‐4 weeks (primary… compared with lithium (low certainty).
Valproate showed no clear difference in individual adverse events ‐ Sedation At 3 weeks (secondary… compared with lithium (low certainty).
Valproate showed no clear difference in dropout rate ‐ All‐cause At 2‐4 weeks (secondary acceptability… compared with lithium (moderate certainty).
It is very uncertain whether valproate changes response rate at 8 weeks (primary efficacy outcome) compared with lithium (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether valproate changes individual adverse events ‐ Sedation At 8 weeks (secondary… compared with lithium (very low certainty).
Valproate probably leads to higher number with any adverse event after 3 weeks (primary tolerability… compared with placebo (moderate certainty).
It is very uncertain whether valproate changes dropout rate ‐ All‐cause At 8 weeks (secondary acceptability outcome) compared with lithium (very low certainty).
Valproate showed no clear difference in response rate at endpoint at 3 weeks (primary efficacy outcome) compared with olanzapine (low certainty).
The review found no eligible studies for this question.
Valproate leads to lower adverse events ‐ Sedation At 3‐12 weeks (secondary tolerability… compared with olanzapine (high certainty).
Valproate showed no clear difference in dropout rate ‐ All‐cause At 3‐12 weeks (secondary acceptability… compared with olanzapine (high certainty).
Valproate may leads to lower response rate at 8 weeks (primary efficacy outcome) compared with risperidone (low certainty).
The review found no eligible studies for this question.
The findings closest to your search, judged one by one by TypeSafe's Jev model.